PerkinElmer Acquires Covaris

New Mountain Capital Makes Majority Investment in Covaris

January 13, 2022

Medical Devices

New Mountain Capital has made a majority investment in Covaris, a Woburn, Massachusetts-based manufacturer of sample preparation instruments, consumables and reagents for genomics and proteomics. Founder Jim Laugharn will remain CEO and Chris O'Connell will serve as Executive Chairman as New Mountain partners with Covaris to accelerate growth and expand the company's sample-prep capabilities.

PerkinElmer Acquires Nexcelom Bioscience for $260M

May 13, 2021

Medical Devices

PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.

New Mountain Capital to Acquire PerkinElmer's Applied, Food and Enterprise Services Businesses

August 1, 2022

Medical Devices

New Mountain Capital entered into a definitive agreement to acquire PerkinElmer's Applied, Food and Enterprise Services businesses (a carve-out from PerkinElmer's Discovery & Analytical Solutions segment) for up to $2.45 billion. The transaction transfers the OneSource lab and field services business and a portfolio of instruments, consumables and reagents to New Mountain, which intends to invest behind the business as a platform for growth; the deal closed in Q1 2023 subject to customary approvals.

PerkinElmer Acquires Cisbio Bioassays from Abénex

April 26, 2019

Biotechnology

PerkinElmer has acquired Cisbio Bioassays from Abénex (with Cisbio management supporting the sale). Cisbio, headquartered in Codolet, France, is a manufacturer of HTRF assay kits, reagents and custom assay services with more than 200 employees; the acquisition expands PerkinElmer's life‑sciences reagent and screening technology portfolio.

PerkinElmer Acquires BioLegend for Approximately $5.25 Billion

July 26, 2021

Biotechnology

PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.

Bruker Corporation Acquires PhenomeX Inc.

August 17, 2023

Biotechnology

Bruker Corporation agreed to acquire PhenomeX Inc. in an all-cash transaction valued at roughly $108 million (purchase price $1.00 per share). PhenomeX — formed from the combination of Berkeley Lights and IsoPlexis and provider of single-cell biology instruments, software and reagents — will be folded into a Bruker subsidiary, marking Bruker’s entry into single-cell biology research tools and complementing its spatial biology offerings.